You are here

P&T® Journal contents for January 2002

Features

In this study, focus groups were conducted with pharmacy benefit decision-makers, to better understand the role of health-related quality-of-life information in the formulary management process.
Thomas Delate, MS, Frank R. Ernst, PharmD, and Stephen Joel Coons, PhD
Continuing Education Credit
The review explains the health and economic benefits of using combination drugs.
Albert Wertheimer, PhD and Alan Morrison, PhD
Drug Shortages (4-Part Series)
In the first article in this four-part series, Dr. Babinchak discusses the scope and consequences of antimicrobial shortages.
Timothy J. Babinchak, MD
New treatments for gram-positive and gram-negative bacteria, rheumatoid arthritis, and migraine, along with a new antiviral drug for the treatment of HIV-1 infection.
Marvin M. Goldenberg, PhD
Continuing Education Credit
The author provides an overview of anticonvulsants approved during the past 25 years for the treatment and management of seizures.
Gale M. Tucker, PharmD, RPh
Drug Shortages (4-Part Series)
One hospital shows how they anticipate and cope with drug shortages.
Noreen H. Chan-Tompkins, PharmD, Roxane Curinga, and Toni Fera, Pharm D
Book Review
A new book gives health care providers evidence-based information on herbal medicine.
Peter Chodoff, MD, MPH
This study analyzed health care claims data to compare the costs of different asthma drug therapies.
Daniel A. Ollendorf, MPH, Alyssa S. Pozniak, BA, Brian W. Bowers, PharmD, and Gerry Oster, PhD
Continuing Education Credit
This article discusses the possible causes of steroid-resistant asthma and treatment for patients who have it.
Stephen B. Moody, MSPharm
Guest Commentary
Do doctors know what’s good for them when they eat at medical conferences?
John La Puma, MD, FACP
Dr. Goldenberg presents recent studies on various cancers and the implications of new and existing therapies.
Marvin M. Goldenberg, PhD
Drug Shortages (4-Part Series)
The results of the ISMP’s recent national survey on drug shortages are discussed, along with guidelines on how to handle drug shortages.
Matthew Grissinger, RPh
This article focuses on the revolutionary new drug that combats a highly complicated disease: sepsis.
Michelle Leady, PharmD, Michael Kraft PharmD, and Cesar Alaniz, PharmD
Despite the widely held belief that therapy with PPIs renders patients asymptomatic, breakthrough symptoms are common.
Malcom Robinson, MD and Kimberly Shaw, BA
Patient self-administered questionnaires could help determine health-related quality of life in outcomes management.
Jennifer Lofland, PharmD
Guest Commentary
Is a placebo-controlled trial ethical if an effective treatment has already been established? The author discusses the issue with Robert Temple, MD.
Miriam Reisman
Drug Shortages (4-Part Series)
When it comes to influenza vaccines, the timing of the distribution can create both shortages and surpluses.
Keiji Fukuda, MD, MPH, Dennis O’Mara, and James A. Singleton, MS

Departments

Matthew Grissinger, RPh, discusses the confusion with concentrated insulin, problems caused by the national fentanyl shortage, and a succinylcholine vial mix-up
Matthew Grissinger, RPh
Editorial
Editor-in-Chief David B. Nash explains the concept of “Graceful Degradation.”
David B. Nash, MD, MBA
Prescription Washington
Stephen Barlas
Drug Forecast
A new semisynthetic antimicrobial to treat respiratory tract infections.
Thomas File, MD
Drug News
The latest information about approvals, indication changes, industry updates, and news from the FDA.
Editorial
David B. Nash, MD, MBA, Editor-in-Chief, goes beyond bar codes to “FindtheDOT.”
David B. Nash, MD, MBA
Drug News
The latest information about approvals, indication changes, industry updates, and news from the FDA.
F. Delbert Moeller, MD, FACOG
Prescription Washington
Stephen Barlas discusses the forthcoming pharmaceutical “Rules of Engagement.”
Stephen Barlas
Drug Forecast
Review of Almotriptan: A 5-HT1B/1D agonist for the treatment of migraine.
Brooke D. Fidler, PharmD
Medication Errors
Matthew Grissinger, RPh, discusses the question of who is to blame for “omission errors.”
Matthew Grissinger, RPh
Editorial
Editor-in-Chief David B. Nash describes how, “FARS and FFIRS” programs can help fight medication errors.
David B. Nash, MD, MBA
Prescription Washington
Stephen Barlas
Drug News
The latest information about approvals, indication changes, industry updates, and news from the FDA.
Medication Errors
Matthew Grissinger, RPh, discusses the possible dangers resulting from careless use of fentanyl patches.
Matthew Grissinger, RPh